US FDA Approves Mesoblast’s Cell Therapy for Graft-Versus-Host Disease
On Wednesday, the U.S. Food and Drug Administration approved Mesoblast’s (NASDAQ: MESO) cell therapy for treating a type of complication […]
US FDA Approves Mesoblast’s Cell Therapy for Graft-Versus-Host Disease Read More »
